menu
    • menu
    [{"orgOrder":0,"company":"Nuvisan GmbH","sponsor":"Bill & Melinda Gates Foundation","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"GERMANY","productType":"Undisclosed","year":"2022","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Discovery","graph3":"Nuvisan GmbH","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Vaginal","sponsorNew":"Nuvisan GmbH \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"2","companyTruncated":"Nuvisan GmbH \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Lisata Therapeutics","sponsor":"University of Cincinnati","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Peptide","year":"2024","type":"Agreement","leadProduct":"Certepetide","moa":"||Alpha-5 integrin","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Discovery","graph3":"Lisata Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lisata Therapeutics \/ University of Cincinnati","highestDevelopmentStatusID":"2","companyTruncated":"Lisata Therapeutics \/ University of Cincinnati"}]

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
    filter

    Year

    filter

    DEALS // DEV.

    filter

    Country

    filter
    Sponsor
    filter

    Therapeutic Area

    filter

    Study Phase

    filter

    Deal Type

    filter

    Product Type

    filter

    Dosage Form

    filter

    Lead Product

    filter

    Target

    refresh Filters
    refresh Reset Filter
    refresh Reset Filter
    price-trend All Developments

    Therapeutic Area by Lead Product

    ForexGraph

    Study Phase by Lead Product

    ForexGraph

    Company by Lead Product

    ForexGraph

    Top Deals by Deal Size (USD bn)

    ForexGraph

    01

    Lisata Therapeutics

    U.S.A arrow
    German Wound Congress
    Not Confirmed

    Lisata Therapeutics

    U.S.A arrow
    German Wound Congress
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Certepetide,Bevacizumab

    Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

    Study Phase : Discovery

    Sponsor : University of Cincinnati

    Deal Size : Undisclosed

    Deal Type : Agreement

    DEALS_DEV arrow-down

    Lisata And Cincinnati University to Research Certepetide for Endometriosis

    Details : Through the agreement, Lisata will evaluate a novel cyclic peptide product candidate, LSTA1 (certepetide), in combination with bevacizumab to treat endometriosis.

    Product Name : LSTA1

    Product Type : Peptide

    Upfront Cash : Undisclosed

    October 28, 2024

    Lead Product(s) : Certepetide,Bevacizumab

    Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

    Highest Development Status : Discovery

    Sponsor : University of Cincinnati

    Deal Size : Undisclosed

    Deal Type : Agreement

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    02

    Nuvisan GmbH

    Germany arrow
    German Wound Congress
    Not Confirmed

    Nuvisan GmbH

    Germany arrow
    German Wound Congress
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Undisclosed

    Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

    Study Phase : Discovery

    Sponsor : Bill & Melinda Gates Foundation

    Deal Size : $9.6 million

    Deal Type : Funding

    DEALS_DEV arrow-down

    NUVISAN Receives US$9.6M Grant for A Multi-Target Drug Discovery Program on Novel Non-Hormonal Contraceptive M...

    Details : The comapany will use the received grant for an integrated program on discovery and early development of novel non-hormonal contraceptive medicines and further optimize the hits to in vivo lead compounds during the hit-to-lead process.

    Product Name : Undisclosed

    Product Type : Undisclosed

    Upfront Cash : Undisclosed

    September 20, 2022

    Lead Product(s) : Undisclosed

    Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

    Highest Development Status : Discovery

    Sponsor : Bill & Melinda Gates Foundation

    Deal Size : $9.6 million

    Deal Type : Funding

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    03

    Celmatix

    U.S.A arrow
    German Wound Congress
    Not Confirmed

    Celmatix

    U.S.A arrow
    German Wound Congress
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Undisclosed

    Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

    Study Phase : Discovery

    Sponsor : Evotec

    Deal Size : Undisclosed

    Deal Type : Partnership

    DEALS_DEV arrow-down

    Evotec Partner Celmatix Achieves Milestone For PCOS Drug Programme

    Details : Novel PCOS drug target, is largely unknown, genomic studies suggest a strong genetic connection from Celmatix-Evotec Alliance, identified by Celmatix, progresses into hit-identification.

    Product Name : Undisclosed

    Product Type : Undisclosed

    Upfront Cash : Undisclosed

    January 18, 2022

    Lead Product(s) : Undisclosed

    Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

    Highest Development Status : Discovery

    Sponsor : Evotec

    Deal Size : Undisclosed

    Deal Type : Partnership

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth